Quinazolinones and their Schiff bases are an important class of heterocyclic systems, enjoying considerable interest on account of their diverse range of biological activities\[[@CIT1]--[@CIT9]\] such as antimicrobial, analgesic and antiinflammatory, anticonvulsant, anticancer, antitubercular, antimalarial, antiviral, antihelmintic and, in particular, very high anticonvulsant activity. Anticonvulsant quinazolinones include methaqualone (1)\[[@CIT10]\], which acts on voltage dependant sodium channels in a manner similar to rilozole (2)\[[@CIT11][@CIT12]\], 2-(chloromethyl)-1-(4-methoxyphenyl)-quinazolin-4(1*H*)-one (3) and 2-methyl-3-(5-phenyl-4,5-dihydroisoxazoli-3-ylamino)quinazolin-4(3*H*)-one (4, [fig. 1](#F0001){ref-type="fig"}). Structural modification of the quinozolines nucleus i.e., introduction of Ph- and -CH~3~group at C2 position\[[@CIT13]\], bromination of benzene ring at C6 and C8, introduction of various substituted phenyl moieties\[[@CIT14]\], bridged phenyl rings\[[@CIT15]\], heterocyclic rings\[[@CIT16]\] and aliphatic moieties\[[@CIT17]\] at position-3 are reported to enhance the anticonvulsant activity. The high anticonvulsant activity of quinazolines is also a consequence of their high membrane permeability\[[@CIT18]\]. Fig. 1Some of potent anticonvulsant compounds. 1 is methaqualone, 2 is rilozole, 3 is 2-(chloromethyl)-1-(4-methoxyphenyl)-quinazolin-4(1*H*)-one (3) and 4 is 2-methyl-3-(5-phenyl-4,5-dihydroisoxazoli-3-ylamino)quinazolin-4(3*H*)-one

Earlier, we had reported\[[@CIT19][@CIT20]\] synthesis and antimicrobial activity of Schiff bases of 3-amino-6,8-dibromo-2-phenyl-quinazolin-4-(3*H*)-ones (9a-l). Taking cognizance of the reported high anticonvulsant activity of the quinazolines, it was decided to synthesize the Schiff bases of 3-amino-quinazolines according to the earlier reported procedure\[[@CIT19][@CIT20]\] and evaluate their anticonvulsant activity.

Synthesis of Schiff bases (9a-l) of 3-amino-6,8-dibromo-2-phenyl-quinazolin-4(3*H*)-ones\[[@CIT19][@CIT20]\] (8) with various substituted aldehydes was achieved by refluxing their equimolar dry ethanol solution for 6 h. The Schiff bases (9a-l) were filtered, dried and recrystallised from absolute ethanol ([fig. 2](#F0002){ref-type="fig"}). All compounds (9a-l) were analyzed using detailed spectroscopic (IR, ^1^H NMR, ^13^C NMR, Mass) and elemental analysis. Fig. 2Synthesis of Schiff bases of 3-amino-6,8-dibromo-2-phenyl quinazolin-4(3*H*)-ones 9(a-l) Synthesis of Schiff bases of 3-amino-6,8-dibromo-2-phenyl quinazolin-4(3*H*)-ones 9a-l from reaction of 8 with different aldehydes a-l, (a) R= Ph-, (b) R= *p*-MeO-Ph-, (c) R= *o*-OH-Ph-, (d) R= p-N(CH~3~)~2~-Ph-, (e) R= *m*-NO~2~-Ph-, (f) R= *p*-Me-Ph-, (g) R= *p*-OH-Ph-, (h) R= *p*-Cl-Ph-, (i) R= *p*-NO~2~-Ph-, (j) R= *m*,m,*p*-(OCH~3~)~3~-Ph-, (k) R= p-OH,m-OMe-Ph-, (l) R=-CH=CH-Ph

The animal study protocols were approved by Institutional Animal Ethics Committee's (IAEC) approval. Anticonvulsant activity of all compounds (9a-l, [Table 1](#T0001){ref-type="table"}) was evaluated by maximal electroshock (MES) method\[[@CIT21]\]. Swiss mice (n=6) of either sex selected by random sampling technique were used for the study. Phenytoin at the dose of 10 mg/kg (i.p.) was administered as standard drug for comparison. The test compounds were suspended in polyethylene glycol in the ratio of 1:9/ml in water and were given i.p. at doses of 100-200 mg/kg body weight. Dosing volume was 0.25 ml per 25 g. The animals were held at suitable position and corneal electrodes were placed on the cornea of the mice and applied 50 mA current for 0.2 sec after half an hour administration of the test compounds. Then the time spent by animals in each phase of convulsion was recorded. Animals in which extensor response was abolished were taken as protected mice. Compound 9l (82.74 %) was found to possess high anticonvulsant activity which is followed by 9g (81.61 %), 9i (81.48 %), 9k (81.48 %), 9j (80.29 %) at the dose of 100 mg/kg. Moderate anticonvulsant activity was observed for the compounds 9e (79.03%) followed by 9d (79.01 %), 9f (77.77 %), 9h (77.77 %), 9c (74.07 %) and 9b (72.88 %). Compound 9a showed very low anticonvulsant activity of (68.14%) at the dose level of 100 mg/kg.

###### 

ANTICONVULSANT ACTIVITY OF COMPOUNDS

  Compounds   Dose (mg / kg)   Flexion phase   Extensor phase                  
  ----------- ---------------- --------------- ---------------- -------------- -------
  9a          100              5.66±0.4375     27.99            4.3±0.21875    68.14
              200              4.62±0.3125     35.52            3.6±0.21875    73.33
  9b          100              5.66±0.4375     21.01            3.66±0.21875   72.88
              200              4.82±0.3125     32.73            3.50±0.21875   74.07
  9c          100              5.66±0.4375     27.99            4.3±0.21875    74.07
              200              4.62±0.3125     35.52            3.6±0.21875    76.29
  9d          100              5.66±0.4375     21.01            3.66±0.21875   79.01
              200              4.82±0.3125     32.73            3.50±0.21875   80.59
  9e          100              4.5±0.21875     37.2             3.5±0.21875    79.03
              200              3.74±0.2187     48.36            3.2±0.15625    82.07
  9f          100              4.5±0.21875     37.2             2.83±0.15625   77.77
              200              3.9±0.21875     45.57            2.62±0.15625   79.25
  9g          100              5.33±0.3125     25.62            2.83±0.15625   81.61
              200              4.9±0.3125      31.62            2.42±0.09375   83.70
  9h          100              5.0±0.3125      30.22            3.0±0.15625    77.77
              200              4.8±0.3125      33.01            2.8±0.15625    79.25
  9i          100              5.3±0.3125      26.03            2.5±0.09375    81.48
              200              4.98±0.3125     30.50            2.2±0.09375    83.70
  9j          100              5.83±0.4375     18.57            3.0±0.15625    80.29
              200              5.1±0.3125      28.83            2.8±0.15625    82.96
  9k          100              5.66±0.4375     20.94            2.5±0.09375    81.48
              200              5.22±0.3125     27.15            2.2±0.09375    84.44
  9l          100              6.5±0.4027      9.21             2.66±0.15625   82.74
              200              5.31±0.3125     25.90            2.30±0.09375   84.07
  Phenytoin   10               4.8±0.3125      32.48            0.00±0.00      100
  Control     \-               7.16±0.5625     \-               13.5±0.6875    \-

Significant error mean method: significant differences with respect to control was evaluated by ANOVA.

Structure activity relationship ([fig. 3](#F0003){ref-type="fig"}, [Table 2](#T0002){ref-type="table"}) for all the compounds was developed on the % protection data of extensor phase at dose of 100 mg/kg. Compounds 9l, g, i, bearing CH=CH-Ph, -p-OH-Ph, -p- NO~2~-Ph moieties, showed maximum % protection of 82.74, 81.61 and 81.48. Moderate % protection of 79.01, 77.77, 74.07 and 72.88 was observed for compounds 9d, f, c, b, respectively, possessing electron donating groups such --*p*-N(CH~3~)~2~-Ph, -*p*-Me-Ph, -*o*-OH-Ph, -*p*-OMe-Ph. However, very low anticonvulsant activity was observed for 9a bearing unsubstituted aromatic ring. TABLE 2STRUCTURE ACTIVITY RELATIONSHIPRActivity-CH=CH-Ph, -*p*-OH-Ph, -NO~2~-PhHigh-N(CH~3~)~2~, -Me-Ph, -*o*-OH-Ph, -OMe-PhModeratePhLow Fig. 3Quinazolone schiff base

In conclusion, the present study indicates that compounds 9l, g, i Possessing styryl, *p*-OH-Ph or -*p*-NO~2~-Ph were found to posses high anticonvulsant activity, which may be attributed extended conjugation in case of 9l or hydrogen bonding ability of para-substituent as in the case of 9g, i. While the compounds 9b, c, d, f bearing electron donating groups (-N(CH~3~)~2,~-Me, -*o*-OH, -OMe), display moderate activity; among the latter para-substituted compound (9d) is most active thereby confirming our earlier inference. On the other hand compound bearing unsubstituted phenyl group showed low activity. These compounds shall serve as 'Lead' molecules for further development.
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